التفاصيل البيبلوغرافية
| العنوان: |
Deep molecular tracking over the 12-yr development of endometrial cancer from hyperplasia in a single patient. |
| المؤلفون: |
Reid, Katherine, Camacho-Vanegas, Olga, Pandya, Deep, Catalina Camacho, Sandra, Rui Fang Qiao, Kalir, Tamara, Padron-Rhenals, Maria M., Beddoe, Ann-Marie, Dottino, Peter, Martignetti, John A. |
| المصدر: |
Cold Spring Harbor Molecular Case Studies; Dec2023, Vol. 9 Issue 4, p1-14, 14p |
| مصطلحات موضوعية: |
MOLECULES, ENDOMETRIAL cancer, HYPERPLASIA, HISTOLOGY, DNA sequencing |
| مستخلص: |
Although the progressive histologic steps leading to endometrial cancer (EndoCA), the most common female reproductive tract malignancy, from endometrial hyperplasia are well-established, the molecular changes accompanying this malignant transformation in a single patient have never been described. We had the unique opportunity to investigate the paired histologic and molecular features associated with the 12-yr development of EndoCA in a postmenopausal female who could not undergo hysterectomy and instead underwent progesterone treatment. Using a specially designed 58-gene next-generation sequencing panel, we analyzed a total of 10 sequential biopsy samples collected over this time frame. A total of eight pathogenic/likely pathogenic mutations in seven genes, APC, ARID1A, CTNNB1, CDKN2A, KRAS, PTEN, and TP53, were identified. A PTEN nonsense mutation p.W111* was present in all samples analyzed except histologically normal endometrium. Apart from this PTEN mutation, the only other recurrent mutation was KRAS G12D, which was present in six biopsy samplings, including histologically normal tissue obtained at the patient's first visit but not detectable in the cancer. The PTEN p.W111* mutant allele fractions were lowest in benign, inactive endometrial glands (0.7%), highest in adenocarcinoma (36.9%), and, notably, were always markedly reduced following progesterone treatment. To our knowledge, this report provides the first molecular characterization of EndoCA development in a single patient. A single PTEN mutation was present throughout the 12 years of cancer development. Importantly, and with potential significance toward medical and nonsurgical management of EndoCA, progesterone treatments were consistently noted to markedly decrease PTEN mutant allele fractions to precancerous levels. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cold Spring Harbor Molecular Case Studies is the property of Cold Spring Harbor Laboratory Press and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
